Acanthosis nigricans
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Ọ na-adịkarị na ndị buru ibu.
relevance score : -100.0%
ReferencesAcanthosis nigricans bụ ngosipụta akpụkpọ anụ nke ọnọdụ dị n'okpuru. Ọ na-apụtakarị n'akpụkpọ anụ dị ka olu (neck), armpits (axilla), groin (inguinal region), navel (umbilicus), forehead, na ebe ndị ọzọ. Ọ na-egosipụta patches gbara ọchịchịrị (brown‑to‑black), velvety, hyperpigmented, nwere akụkụ edoghị anya. A na-ejikọkarị ọnọdụ a na orịa shuga (diabetes mellitus), nguzogide insulin (insulin resistance), hyperinsulinemia, yana obesity. Ọzọkwa, a na-ahụkarị ya na hypothyroidism, acromegaly, polycystic ovary disease (PCOS), Cushing's disease, na n’ọnọdụ ndị ọzọ metụtara endocrine dysfunction. Ụmụ mmadụ nke dị afọ 40 ma ọ bụ obere, ndị nwere genetic inheritance, nwere ike inwe ya. N'ọnọdụ ndị a na-adịghị ahụkebe, Acanthosis nigricans nwere ike igosi ọrịa kansa n'ime ahụ (internal malignancy). O nwekwara ike ịpụta n'ihi nsogbu homonụ (hormonal disorders) ma ọ bụ site n'ịṅụ systemic glucocorticoids na ọgwụ mgbochi ịmụ nwa (oral contraceptives). Treatment — OTC Drugs: 40% urea cream.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) bụ ọnọdụ akpụkpọ anụ nke jikọtara ya na nsogbu ahụike dị iche iche dị ka nguzogide insulin, diabetes mellitus (orụịa shuga), oke ibu, ụfọdụ ọrịa kansa (cancer), endocrine disorders (nsogbu hormonal), na mmeghachi omume nke ọgwụ. Ịgwọ AN na-elekwasị anya n'ịgbasa nsogbu ahụike na-akpata. Na mbụ, ndị dọkịta na-enyocha ihe ịrịba ama nke ọrịa na-egbochi insulin, nke gụnyere oke ibu, dyslipidemia (cholesterol dị elu), hypertension (ọbara mgbali elu), na diabetes mellitus type II (ụdị ọrịa shuga 2). Ndị dọkịta na-edekarị topical retinoids dị ka nhọrọ ọgwụgwọ mbụ, nke nwere ike inye aka na ịgbatị akpụkpọ ahụ. Otú ọ dị, ha nwere ike ọ gaghị akọwacha hyperkeratosis (agbachi akpụkpọ) n'ụzọ zuru ezu. Nhọrọ ọgwụgwọ ndị ọzọ (salicylic acid, podophyllin, urea, calcipotriol) chọkwara ngwa ugboro ugboro.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Ihe kpatara
Ọ na-emekarị n’ime ndị na-erubeghị afọ 40, nwere ike ketara ya site na mkpụrụ ndụ ihe nketa ma jikọta ya na oke ibu ma ọ bụ endocrinopathy, dị ka hypothyroidism, acromegaly, polycystic ovary disease, insulin‑resistant diabetes ma ọ bụ ọrịa Cushing.
○ Ọgwụgwọ ― OTC Ọgwụ
#40% urea cream